Cellular Mechanisms of Multiple Myeloma Bone Disease
Open Access
- 1 January 2013
- journal article
- review article
- Published by Hindawi Limited in Clinical and Developmental Immunology
- Vol. 2013, 1-11
- https://doi.org/10.1155/2013/289458
Abstract
Multiple myeloma (MM) is a hematologic malignancy of differentiated plasma cells that accumulates and proliferates in the bone marrow. MM patients often develop bone disease that results in severe bone pain, osteolytic lesions, and pathologic fractures. These skeletal complications have not only a negative impact on quality of life but also a possible effect in overall survival. MM osteolytic bone lesions arise from the altered bone remodeling due to both increased osteoclast activation and decreased osteoblast differentiation. A dysregulated production of numerous cytokines that can contribute to the uncoupling of bone cell activity is well documented in the bone marrow microenvironment of MM patients. These molecules are produced not only by malignant plasma cells, that directly contribute to MM bone disease, but also by bone, immune, and stromal cells interacting with each other in the bone microenvironment. This review focuses on the current knowledge of MM bone disease biology, with particular regard on the role of bone and immune cells in producing cytokines critical for malignant plasma cell proliferation as well as in osteolysis development. Therefore, the understanding of MM pathogenesis could be useful to the discovery of novel agents that will be able to both restore bone remodelling and reduce tumor burden.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG_11957)
This publication has 124 references indexed in Scilit:
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseProceedings of the National Academy of Sciences of the United States of America, 2010
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaBlood, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Foxp3+natural regulatory T cells preferentially form aggregates on dendritic cellsin vitroand actively inhibit their maturationProceedings of the National Academy of Sciences of the United States of America, 2008
- A soluble activin Type IIA receptor induces bone formation and improves skeletal integrityProceedings of the National Academy of Sciences of the United States of America, 2008
- Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivoBlood, 2008
- MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclastsBlood, 2007
- Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cellsBlood, 2006
- Regulation of bone mass by Wnt signalingJCI Insight, 2006
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004